Biosimilars and Biobetters
|Event Date/Time: Sep 22, 2010||End Date/Time: Sep 23, 2010|
|Early Registration Date: May 28, 2010|
Biosimilars have attracted a great deal of interest recently and is seen by some as the new generic frontier, since it is widely thought that lower levels of competition will lead to higher margins in an industry notorious for its generally low margins on commodity generics. Payer pressure is expected to drive uptake, particularly in the German, UK and US markets.
Hear from experts in this field discuss the latest developments in legislation, regulation, technology and emerging commercial strategies to succeed in this highly competitive market.
Key topics include:
â€¢ Worldwide regulatory updates
â€¢ The developing US follow-on biologics framework
â€¢ The challenges in biosimilar commercialisation
â€¢ How biobetters fit into a long term commercial strategy
â€¢ Legal and IP developments
â€¢ Biosimilar and biobetter monoclonal antibodies
â€¢ Opportunities to drive a long term commercial strategy
â€¢ Effectively leveraging licensing opportunities
â€¢ Biosimilar quality aspects
Plus a half day pre-conference workshop:
Biosimilars: Understanding the Regulatory Processes and the Commercial Realities
1.00 â€“ 5.00pm â€“ 21st September 2010, Crowne Plaza London â€“ The City, London, UK
Hosted by: Peter Wittner, Senior Consultant, Interpharm Consultancy
The aim of this workshop is to give participants a good overview of the whole topic of biosimilars while investigating in more depth those topics that merit it.
It brings together leading experts from the industry to examine the latest developments and technologies to drive a successful biosimilar strategy